20 October 2020 - The Biosafety Advisory Council issues a positive advice (with conditions) for this deliberate release
File:
Trial reference:
A Phase I/IIa study of intra-tumoral BT-001 (TG6030) administered alone and in combination with pembrolizumab in patients with cutaneous or, subcutaneous lesions or easily injectable lymph nodes of metastatic/advanced solid tumors